Výsledky vyhledávání - "Catherine L Shuler"

Akademický článek

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Autor: Laura C. Coates, Ana-Maria Orbai, Akimichi Morita, Olivier Benichou, Lisa Kerr, David H. Adams, Catherine L. Shuler, Julie Birt, Philip S. Helliwell

Publikováno v: BMC Rheumatology, Vol 2, Iss 1, Pp 1-8 (2018)

Abstract Background Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients. We sought to evaluate whe

Externí odkaz: https://doaj.org/article/3c6b599d6f0d4d9c8cdafedeb553f9c3

Zobrazit plný text záznamu

Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Autor: Philip S. Helliwell, J. Erickson, Eric Lespessailles, Hideto Kameda, Roy Fleischmann, Ruben Burgos-Vargas, S. Rathmann, Vinod Chandran, Catherine L Shuler, Gaia Gallo, Désirée van der Heijde, Aubrey Trevelin Sprabery, Julie Birt

Publikováno v: Rheumatology, 59(10), 2774-2784. OXFORD UNIV PRESS
Rheumatology
Rheumatology, Oxford University Press (OUP), 2020, 59 (10), pp.2774-2784. ⟨10.1093/rheumatology/kez684⟩
Rheumatology (Oxford, England)

Objective The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. Methods In a phase III study, patients naïve to biologic treatment were randomized to placebo, adalimumab 40 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22351d4deab772a061099af31fb50c3b
https://academic.oup.com/rheumatology/article/59/10/2774/5730209

Zobrazit plný text záznamu

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies

Autor: Alice B. Gottlieb, Arthur Kavanaugh, Joseph F. Merola, Diamant Thaçi, Matthew M. Hufford, Julie Birt, Akimichi Morita, Chen-Yen Lin, Catherine L Shuler

Publikováno v: Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, vol 78, iss 9

ObjectiveDetermine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA).MethodsSPIRIT-P1 and SPIRIT-P2 are phase 3 trials investigating ixekizumab, an interleukin-17A ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b5e6b93c2ea7f86b5dce8e475a8d73c
https://pubmed.ncbi.nlm.nih.gov/31113794

Zobrazit plný text záznamu

Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)

Autor: Beth A. Pangallo, K. Callis Duffin, Lotus Mallbris, M. Bukhalo, Anne M. Gill, S.L. Choi, Catherine L Shuler, Jerry Bagel, I.J. Mercado Clement, K. Jackson, Fangyi Zhao

Publikováno v: Journal of the European Academy of Dermatology and Venereology

Background The efficacy of ixekizumab, an anti‐interleukin‐17A (anti‐IL‐17A) monoclonal IgG4 antibody, was demonstrated in moderate‐to‐severe psoriasis patients when administered via prefilled syringe (PFS). Objective To evaluate the effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb90727a516e03471d1adf1296ffd4e
https://doi.org/10.1111/jdv.13768

Zobrazit plný text záznamu

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Autor: Dafna D. Gladman, Masato Okada, Philip J. Mease, Christopher T. Ritchlin, Daniel K. Braun, Chin Lee, Désirée van der Heijde, R. Cuchacovich, Chen-Yen Lin, Catherine L Shuler

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 76(1), 79-87

ObjectiveTo assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA).MethodsPatients naive to biologic therapy with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0110d8ba845044874a894a8071a17b7b
http://europepmc.org/articles/PMC5264219

Zobrazit plný text záznamu

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Autor: Catherine L Shuler, Philip S. Helliwell, Akimichi Morita, Olivier Bénichou, Laura C. Coates, Julie Birt, David H. Adams, Lisa Kerr, Ana Maria Orbai

Publikováno v: BMC Rheumatology, Vol 2, Iss 1, Pp 1-8 (2018)
BMC rheumatology

Background Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients. We sought to evaluate whether achi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c67bebe56f6d23eb468b6c5713d749
https://doi.org/10.1186/s41927-018-0030-y

Zobrazit plný text záznamu

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Autor: Alice B. Gottlieb, Catherine L Shuler, Chin Hyok Lee, Mitsumasa Kishimoto, Philip J. Mease, Chen-Yen Lin, Laura C. Coates

Publikováno v: RMD Open

Objective To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analys

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2313e7dc3c136ad3cff553775b0ded5b
https://doi.org/10.1136/rmdopen-2017-000567

Zobrazit plný text záznamu

THU0333 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)

Autor: Catherine L Shuler, Roy Fleischmann, J. Erickson, P S Helliwell, Eric Lespessailles, Vinod Chandran, Olivier Bénichou

Publikováno v: THURSDAY, 14 JUNE 2018.

Background Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. IXE, every 4 (Q4W) or 2 (Q2W) weeks, was superior to placebo (PBO) in improving the signs and symptoms of psoriatic arthritis (PsA) at Week 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df3476a439bdce09702d9c89bacd84a0
https://doi.org/10.1136/annrheumdis-2018-eular.2137

Zobrazit plný text záznamu

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Autor: Chen-Yen Lin, Diamant Thaçi, Catherine L Shuler, Julie Birt, Philip J. Mease, Chin Lee, Mitsumasa Kishimoto, Dafna D. Gladman, Vibeke Strand, Alice B. Gottlieb

Publikováno v: Rheumatology (Oxford, England). 57(10)

Objective To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52 weeks. Methods In SPIRIT-P1, biologic-naive patients with active PsA were randomized to ixekizumab 80 mg every 4 weeks (IXEQ4W; N = 107) or every 2 we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869584fa83539dabdc752c204e36a086
https://pubmed.ncbi.nlm.nih.gov/29945203

Zobrazit plný text záznamu

Efficacité et sécurité de l’ixékizumab chez des patients ayant un rhumatisme psoriasique actif : résultats à 3 ans d’une étude de phase 3 (SPIRIT-P1)

Autor: Vinod Chandran, Roy Fleischmann, Catherine L Shuler, Olivier Bénichou, Eric Lespessailles, J. Erickson, E. Seban, P S Helliwell

Publikováno v: Annales de Dermatologie et de Vénéréologie. 145:S356-S357

Introduction L’ixekizumab (IXE) est un anticorps monoclonal de haute affinite qui cible de maniere selective l’interleukine-17A. L’IXE, administre toutes les 4 (Q4 W) ou 2 semaines (Q2 W) a ete superieur au placebo sur l’amelioration des sign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3f2f0c020bb3d8880f214cf73efcb9e
https://doi.org/10.1016/j.annder.2018.09.587

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání